Immunovative Therapies to raise $2m for human trials

The company will conduct its trial in California on 50 cancer patients in the first phase.

Biopharmaceutical company Immunovative Therapies td. is seeking to raise $2 million after receiving approval from the US Food and Drug Administration (FDA) to start human trials for its anticancer drug. To date the company has raised $4.5 million.

The company, which is located in the Misgav Technology Center, develops bone marrow/stem cell transplant procedures to cure advanced cancers that do not respond to other treatments.

Immunovative Therapies will conduct its human trials in California and in the first phase will include 50 patients with advanced lung, liver and bone cancers. Earlier trials focused on safety and effectiveness.

Published by Globes [online], Israel business news - - on September 8, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018